Skip to main content
. 2020 Dec 11;10(1):415–432. doi: 10.1007/s40122-020-00223-y

Table 2.

Concomitant conditions in TIRs and TSRs (PRF data)

Concomitant conditions, n (%) Total (N = 200) TIRs (n = 88) TSRs (n = 112) p value
Neck pain 26 (13.0) 13 (14.8) 13 (11.6) 0.509a
Anxiety 9 (4.5) 5 (5.7) 4 (3.6) 0.511b
Stress 13 (6.5) 5 (5.7) 8 (7.1) 0.677a
Sleep disorders 8 (4.0) 3 (3.4) 5 (4.5) 1.000b
Depression 5 (2.5) 3 (3.4) 2 (1.8) 0.656b
Asthma/allergic rhinitis 9 (4.5) 4 (4.5) 5 (4.5) 1.000b
Back pain 4 (2.0) 2 (2.3) 2 (1.8) 1.000b
Thyroid disease 1 (0.5) 0 1 (0.9) 1.000b
No. of diagnosed concomitant conditions, mean (SD) 0.59 (1.0) 0.56 (0.8) 0.62 (1.1) 0.664c
Currently has a cardiovascular condition, n (%) 27 (13.5) 12 (13.6) 15 (13.4) 0.960a
Hypertension 25 (12.5) 10 (11.4) 15 (13.4) 0.667a
Angina 1 (0.5) 0 1 (0.9) 1.000b
Otherd 3 (1.5) 2 (2.3) 1 (0.9)
Current cardiovascular risk,e n (%) 0.821a
 Mild 169 (86.7) 74 (86.0) 95 (87.2)
 Moderate 26 (13.3) 12 (14.0) 14 (12.8)

Percentages are calculated as proportion of non-missing data

PRF patient record form (completed by the physician), SD standard deviation, TIR triptan insufficient responders (based on efficacy), TSR triptan sufficient responders (based on efficacy)

aChi-square test for TSRs versus TIRs

bFisher’s exact test for TSRs versus TIRs

ct test for TSRs versus TIRs

dNo patient in either group had cerebrovascular disease, ischemic heart disease, congestive heart failure, hypotension, atrial fibrillation, arrhythmia, deep vein thrombosis, cardiomyopathy, coronary artery disease, peripheral vascular disease, mitral valve disease, or Raynaud’s disease

eSubjective opinion of the physician; no patient was assessed as being at severe risk